Raw data of this study_pla2r_TAC_iMN.xlsx

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y
1	patient	clinical diagnosis	pathologic diagnosis	initial immunosuppressive therapy	Trough blood concentration of TAC	autoantibody detection time	autoantibody quantification(RU/ml)	gender	age	weight(kg)	systolic pressure(mmHg)	diastolic pressure(mmHg)	Hb(g/L)	proteinuria(g/24h)	Alb(g/L)	Total protein(g/L)	TC(mmol/L)	TG(mmol/L)	LDL(mmol/L)	BUN(mmol/L)	SCr(μmol/L)	eGFR	Follow-up time (months)	clinical remission	complications and drug-related side effects

2	1	NS	MN	TAC+glucocorticoid	6.4	2017/5/1	53.52	F	55	52	162	94	104	4.18	22.1	41.2	2.25	2.25	6.22	7.6	85.2	66.47	34	5P，7C
3	2	NS	MN	TAC+glucocorticoid	4.7	2017/5/1	82.89	F	48	66	138	94	124	5.7	26.7	49	4.75	4.39	2.32	3.6	54.8	106.98	28	1P，11C	Diabetes
4	3	NS	MN	TAC	3.1	2018/1/1	82.04	M	56	59	126	84	126	2.38	16.3	36.8	5.88	2.69	3.66	4.2	68.5	101.18	30	7P，9C
5	4	NS	MN	TAC	5.1	2018/1/1	568.67	F	64	63	111	64	102	7.06	22.3	49.4	11.62	3.64	8.99	6.2	52.5	96.96	24	0	ESRD、upper respiratory tract infection
6	5	NS	MN	TAC+glucocorticoid	4.3	2018/1/1	883.42	M	71	72	144	69	115	1.97	22	48	9.61	1.5	7.93	6	83	81.36	9	0	catheter associated infection、ESRD、death
7	6	NS	MN	TAC	5.2	2018/2/1	208.64	M	51	61	100	85	135	1.33	29.7	48.6	7.82	1.72	5.74	6.8	61.7	109.40	42	0
8	7	NS	MN	TAC	6.7	2018/2/1	213.63	F	59	62	158	81	142	2.29	29.8	45.6	4.75	1.71	2.9	6.2	62	94.92	41	17P，22C	Diabetes
9	8	NS	MN	TAC+glucocorticoid	3.1	2018/2/1	1088.71	F	77	55	158	86	100	4.13	16.2	39.8	10.58	1.59	9.11	14.4	128	34.82	24	0	ESRD、pulmonary infection
10	9	NS	MN	TAC	4.7	2018/3/1	46.86	M	50	56	103	65	132	4.3	18.6	43.7	6.06	0.69	4.1	5.7	72.6	103.04	38	1P，12C	Pulmonary infection
11	10	NS	MN	TAC+glucocorticoid	6.4	2018/3/1	370.52	F	65	55	139	82	118	3.51	21.4	43.1	10.01	1.55	7.02	4.5	44.7	101.52	40	4P	Diabetes、secondary pulmonary tuberculosis、conjunctivitis、urinary tract infection
12	11	NS	MN	TAC	4.7	2018/4/1	263.33	M	70	69	126	89	130	8.05	20.6	48.1	7.22	5.7	3.99	6.2	63.2	94.79	24	0
13	12	NS	MN	TAC	3.9	2018/5/1	39.53	F	64	57	129	91	88	4.94	22.2	44.1	6.85	2.1	5.12	4.5	53.2	96.54	30	0
14	13	NS	MN	TAC	3.3	2018/5/1	564.93	F	81	53	104	63	116	6.34	22.3	51.9	8.49	2.29	6.24	10.5	128.4	33.73	9	0	ESRD、death
15	14	NS	MN	TAC	4.8	2018/6/1	36.48	F	48	58	120	67	110	4.1	23.3	48.3	4.55	0.79	2.39	6.4	67.9	91.87	8	8PR
16	15	NS	MN	TAC	5.3	2018/6/1	40.9	F	58	67	129	84	130	7.36	24.2	52	6.99	4.57	4.62	7.2	89.6	61.24	34	6PR，34CR
17	16	NS	MN	TAC	5.5	2018/6/1	636.35	M	75	62	134	82	134	5.61	24.9	55	6.33	2.27	3.78	7.6	80.2	82.45	24	0	ESRD
18	17	NS	MN	TAC	6.9	2018/8/1	288.82	M	82	54	101	72	130	2.05	19.2	38.6	5.58	3.93	3.91	4.4	52.7	93.88	6	0	ESRD、death
19	18	NS	MN	TAC+glucocorticoid	7.9	2018/8/1	367.88	M	61	71	152	91	121	10.51	13.7	43.3	7.52	3.94	5.51	6.3	96.2	73.01	17	0	Diabetes、infection
20	19	NS	MN	TAC+glucocorticoid	7.4	2018/9/1	111.44	F	55	65	117	85	130	3.74	25.2	51.5	11.64	4.06	8.81	6.2	57.5	100.24	23	10P
21	20	NS	MN	TAC+glucocorticoid	3.2	2018/9/1	883.42	M	51	65	138	86	104	5.89	17.5	35.1	5.15	1.55	3.95	7.3	83.2	93.36	34	0
22	21	NS	MN	TAC+glucocorticoid	6.2	2018/10/1	270.29	F	35	64	125	85	144	7.82	23.1	50	5.84	1.28	3.42	3.6	59.1	114.33	9	3P
23	22	NS	MN	TAC+glucocorticoid	8.1	2018/11/1	26.7	M	64	59	146	78	127	3.51	22.7	42.2	6.01	0.78	3.68	5	75.4	91.95	17	1P，5C
24	23	NS	MN	TAC	8.1	2018/11/1	42.17	F	61	60	111	79	130	5.86	28.3	49.6	5.1	2.84	3.33	6.1	45.2	104.03	33	3PR，5CR
25	24	NS	MN	TAC+glucocorticoid	6.1	2018/11/1	124.95	F	55	63	139	93	98	3.46	29.8	50.1	5.1	4.32	2.8	5.1	73.2	79.87	28	4P，11C
26	25	NS	MN	TAC+glucocorticoid	5.8	2018/11/1	550.11	M	47	63	139	88	134	7.66	20.4	42	13.13	3.99	10.27	5.3	112.1	66.96	29	2P，22C
27	26	NS	MN	TAC+glucocorticoid	6.2	2018/12/1	21.16	F	82	61	147	74	80	1.38	30.3	48.4	5.75	1.66	3.67	22	128	33.62	30	6P，18C	AKI、peritonitis、herpes zoster
28	27	NS	MN	TAC+glucocorticoid	8.9	2018/12/1	52.27	M	21	75	146	94	100	8.53	17.1	29.9	4.47	1.19	2.73	9.1	103.4	88.62	25	7P	Cellulitis of lower limbs
29	28	NS	MN	TAC+glucocorticoid	6	2018/12/1	206.52	M	65	49	127	66	104	8.68	20.6	44.3	11.06	1.27	9.22	5.5	56.2	103.03	34	0
30	29	NS	MN	TAC+glucocorticoid	5.3	2018/12/1	453.18	M	47	76	124	90	143	2.2	18	43.3	10.28	4.44	7.45	5	87.2	90.72	32	0
31	30	NS	MN	TAC	8.1	2019/1/1	24.36	M	64	62	162	82	85	5.36	22.4	50.1	5.68	1.06	3.24	6.3	86	81.87	7	7P
32	31	NS	MN	TAC	7.1	2019/1/1	32.51	M	48	74	128	93	148	1.57	34.2	60.1	6.64	1.4	5.21	4.7	69.3	106.52	30	7P，12C
33	32	NS	MN	TAC	3.2	2019/1/1	40.92	M	49	74	129	78	166	6.18	19.4	43.6	14.82	4.17	12.39	5	70.7	104.91	24	2P，7C
34	33	NS	MN	TAC+glucocorticoid	6.4	2019/1/1	135.89	F	73	54	125	62	110	6.4	19.7	44.7	8.4	3.21	6.22	10.2	74.3	69.12	22	6P
35	34	NS	MN	TAC+glucocorticoid	7.3	2019/1/1	374.57	M	48	85	193	99	128	3.68	12.4	31.4	9.17	1.4	7.22	4.2	78.9	100.99	30	10P
36	35	NS	MN	TAC+glucocorticoid	5.2	2019/3/1	40.74	M	54	79	137	93	159	4.83	19.4	44.9	14.53	4.05	11.79	5.8	102.2	71.28	24	13P	Diabetes、pulmonary infection、herpes zoster
37	36	NS	MN	TAC+glucocorticoid	7.9	2019/3/1	56.29	M	42	68	106	64	153	2.52	21.3	43.4	15.14	3.22	9.97	5.8	104.6	75.41	22	3P，12C
38	37	NS	MN	TAC+glucocorticoid	3.7	2019/3/1	127.02	M	52	81	146	93	152	3.7	16.7	36	8.59	3.91	6.45	4.2	77.2	99.07	20	0
39	38	NS	MN	TAC+glucocorticoid	5.8	2019/3/1	128.03	F	57	73	153	96	123	4.62	15.9	41.7	9.39	9.75	4.89	5.2	50.2	103.36	16	2P，12C
40	39	NS	MN	TAC	8.2	2019/3/1	134.56	M	73	72	179	100	120	5.31	29	53.9	6.18	2.59	3.96	4.4	67.7	90.23	29	0	Diabetes、ESRD、catheter associated infection（twice）
41	40	NS	MN	TAC	7.1	2019/3/1	172.02	F	62	58	134	78	124	2.11	24.6	47.8	10.16	3.19	7.8	5	56.9	95.76	6	0
42	41	NS	MN	TAC	9	2019/3/1	326.73	M	40	60	128	84	144	2.99	17.9	38.9	13.38	2.55	11.46	4	74.1	109.62	28	8P，20C
43	42	NS	MN	TAC	6.7	2019/3/1	578.06	M	69	71	115	80	108	5.18	19.8	37.1	6.24	2.53	4.57	4.7	112	57.43	28	0	Pulmonary infection、ESRD
44	43	NS	MN	TAC	5.4	2019/4/1	55.98	M	35	80	108	65	123	7.01	16.2	40.2	10.08	3.77	7.01	7	97	86.77	27	8P，12C
45	44	NS	MN	TAC	3.5	2019/4/1	74.98	M	48	70	122	86	150	3.65	25.5	46	6.41	3.76	3.4	4	96.5	79.69	16	4P，16C
46	45	NS	MN	TAC	6.2	2019/4/1	119.31	M	53	67	110	78	138	2.66	20.6	46.7	11.58	1.59	9.41	5.3	58.3	110.41	20	5P，12C
47	46	NS	MN	TAC	3.9	2019/4/1	197.72	F	43	55	117	78	96	6.22	15.2	37.2	13.2	3.39	11.53	2.6	61	106.96	19	9P，13C	Pulmonary infection
48	47	NS	MN	TAC+glucocorticoid	4.8	2019/4/1	221.98	F	29	57	108	80	125	3.76	21.3	44.3	12.3	1.64	10.08	4.1	55.3	121.89	28	5P，8C
49	48	NS	MN	TAC	7.9	2019/4/1	331.9	F	62	60	162	84	113	4.61	24.1	52.2	12.16	2.14	8.87	4.4	60.4	93.90	19	4P，13C
50	49	NS	MN	TAC	3.3	2019/4/1	366.87	F	46	70	108	85	103	1.44	19.4	36	5.24	1.01	3.8	3.8	56.5	107.40	27	11P，13C
51	50	NS	MN	TAC+glucocorticoid	5.4	2019/4/1	519.34	F	66	62	113	75	106	3.88	18.4	42.8	12.78	1.73	10.22	2.8	77.5	69.00	27	4P
52	51	NS	MN	TAC	7.3	2019/5/1	36.9	M	40	82	102	78	180	4.25	26.6	49.7	8.09	3.32	6.72	4.6	78.3	107.16	26	16P
53	52	NS	MN	TAC+glucocorticoid	6.2	2019/5/1	146.21	M	73	52	125	83	121	4.51	21	39.6	5.66	1.36	3.38	6.4	63.8	92.45	25	7P，18C	Diabetes
54	53	NS	MN	TAC	3.4	2019/6/1	38.65	M	49	69	119	78	162	3.6	25.8	54.6	15.3	6.53	11.45	3.7	83.9	93.72	24	9P，13C
55	54	NS	MN	TAC	5.2	2019/6/1	43.91	M	47	60	127	89	161	2.83	31.3	72.2	7.85	1.84	5.49	5.2	72.2	105.48	20	3P，9C
56	55	NS	MN	TAC+glucocorticoid	7.7	2019/6/1	101.02	M	37	79	134	91	157	5.97	22.1	45.3	8.77	8.91	4.68	2.5	86.1	98.82	14	2P，5C
57	56	NS	MN	TAC+glucocorticoid	7.6	2019/6/1	189.99	M	50	67	125	87	143	3.91	21.7	45.4	8.61	2.55	6.75	3.9	89.9	85.61	24	2P，11C
58	57	NS	MN	TAC+glucocorticoid	4.4	2019/6/1	956.52	M	53	74	147	103	116	1.93	15.9	39.1	6.87	4.39	4.25	9.2	160	41.75	26	9P
59	58	NS	MN	TAC	5.8	2019/7/1	69.42	M	60	57	120	86	126	1.09	18.6	41.9	5.12	1.91	3.03	5.5	85.9	84.32	21	4P，8C	Pulmonary infection
60	59	NS	MN	TAC	5.8	2019/7/1	114	M	55	73	134	88	126	3.17	29.8	53.8	6.38	7.87	2.3	4.2	80.9	93.90	20	8P，11C
61	60	NS	MN	TAC+glucocorticoid	5.4	2019/7/1	117.26	M	59	60	134	86	132	2.73	13.5	30.7	6.89	3.51	4.72	17.5	141.5	46.44	25	12P
62	61	NS	MN	TAC	6.5	2019/7/1	260	M	54	73	120	78	129	5.35	14.9	39.9	8.85	5.91	5.62	5.1	81.2	94.14	25	0
63	62	NS	MN	TAC	3.5	2019/7/1	782	F	85	53	165	84	118	1.63	18.5	48.5	7.65	3.03	5.05	6.5	73.8	64.05	25	0	Pulmonary infection、ESRD
64	63	NS	MN	TAC	6.5	2019/8/1	37	F	59	60	137	86	126	5.4	26.9	55.3	9.6	3.6	7.47	7.5	45.7	105.12	23	11P，15C	Plasma exchange、upper respiratory tract infection
65	64	NS	MN	TAC	3.8	2019/9/1	423	M	50	60	128	77	139	0.68	13.3	39.6	7	2.04	5	5.1	132.8	53.42	23	0	Cellulitis of lower limbs
66	65	NS	MN	TAC	6.4	2020/4/1	26	M	63	82	137	87	153	4.17	35.9	64.4	6.1	1.56	4.28	4.3	72.4	94.16	10	2P，10C	Diabetes
67	66	NS	MN	TAC+glucocorticoid	5.2	2019/9/1	460.86	M	56	58	124	78	131	3.79	26.2	47.6	6.74	2.12	4.6	4.1	55.4	147.37	9	9PR	Pulmonary infection、Diabetes
68	67	NS	MN	TAC	4.9	2019/10/1	46.55	M	53	68	147	94	137	6.75	23.8	43.2	6.05	2.36	3.93	4	82.2	95.87	13	6PR，11CR
69	68	NS	MN	TAC	7.2	2019/10/1	379.25	M	56	75	137	93	153	5.18	24.9	50.6	9.67	4.42	7.07	4	71.9	81.04	17	14PR
70	67	NS	MN	TAC+glucocorticoid	6.1	2019/10/1	35.88	F	73	55	130	70	94	5.2	21	43.5	8.76	1.84	6.45	13.2	62	86.03	20	11PR
71	70	NS	MN	TAC	5.9	2019/11/1	27.08	F	57	51	120	79	121	6.46	27.7	58.1	7.19	4.53	4.97	5.4	63.9	123.14	13	13PR
72	71	NS	MN	TAC+glucocorticoid	4.2	2019/11/1	39.57	M	59	63	152	91	118	3.85	27.8	48.5	7.95	1.29	5.01	14	127.6	76.72	13	10PR	Diabetes
73	72	NS	MN	TAC	7.8	2019/12/1	121.3	M	45	70	140	83	138	5.26	27.9	52.7	5.28	2.27	3.29	4	59.6	115.74	9	9NR
74	73	NS	MN	TAC	6.2	2020/1/1	149.2	M	65	60	125	82	129	3.44	26.2	52.7	5.15	1.15	3.22	4.8	63.2	98.18	17	10PR
75	74	NS	MN	TAC	4.8	2020/4/1	142.79	M	70	65	149	77	117	3.64	21.2	44.1	10.22	1.93	8.28	6.2	85	79.60	12	0
76	75	NS	MN	TAC+glucocorticoid	5.9	2020/4/1	196.88	M	66	62.5	138	85	110	13.95	17	46.7	7.65	2.01	5.3	6.8	113.6	57.66	15	0
77	76	NS	MN	TAC	5.7	2020/5/1	374.05	F	76	45	151	86	122	9.32	27	54.5	8.98	3.53	6.75	4.4	70.6	71.99	12	0	Pulmonary infection
78	77	NS	MN	TAC	8	2020/5/1	329.8	F	55	60.5	135	82	129	5.65	26.3	50.2	9.17	1.12	6.12	2.86	61.4	98.10	9	0
79	78	NS	MN	TAC	6.2	2020/5/1	142.49	M	67	64	146	87	97.5	4.94	21.9	46.2	6.77	1.85	5.06	4.6	76.2	89.64	13	5PR
80	79	NS	MN	TAC+glucocorticoid	6.7	2020/6/1	112.38	F	28	70	132	92	144	4.94	25.3	48.7	8.11	2.97	4.3	3.1	54.1	123.63	13	2PR，6CR	upper respiratory tract infection
81	80	NS	MN	TAC+glucocorticoid	7.9	2020/6/1	380.32	M	47	78	132	93	124	5.34	23.4	47.3	6.44	1.31	4.59	5.58	106.9	70.92	16	4PR	Urinary tract infection、Diabetes
82	81	NS	MN	TAC+glucocorticoid	5.3	2020/6/1	361.91	M	44	67	106	72	143	5.23	17.4	39.4	10.24	3.06	8.24	5.1	78.4	104.14	9	0
83	82	NS	MN	TAC	4.7	2020/6/1	＞1500	F	62	63.5	156	88	122	9.46	27.1	53.8	6.82	2.38	4.76	6.8	65	87.78	15	0	Diabetes
84	83	NS	MN	TAC	7.5	2020/6/1	170.09	F	63	52.5	127	85	117	4.58	21.3	51.3	7.09	3.24	4.4	3.4	54.9	96.22	13	9PR，13CR
85	84	NS	MN	TAC+glucocorticoid	5.5	2020/6/1	39.66	M	49	70	140	90	118	3.06	18.7	42	10.89	1.65	8.71	4.76	110	67.55	13	2PR
86	85	NS	MN	TAC+glucocorticoid	3.9	2020/7/1	140.22	M	61	55	118	79	148	3.4	18.5	48.2	9.7	3.7	5.63	3.6	68.1	97.92	12	3PR
87	86	NS	MN	TAC	4.7	2020/7/1	97.39	M	44	64	120	78	147	3.58	21.6	43	6.83	2.03	4.36	5.4	92.3	86.50	12	2PR，6CR
88	87	NS	MN	TAC+glucocorticoid	4.6	2020/7/1	120.47	F	45	50	128	88	104	7.62	20.2	43.8	5.5	1.48	3.74	5.1	89.7	67.01	8	1PR，8CR
89	88	NS	MN	TAC	5.4	2020/7/1	75.67	M	68	82	130	76	86	3.77	19	39.7	8.44	1.93	6.63	6.8	73.2	90.50	12	9PR
90	89	NS	MN	TAC+glucocorticoid	4.3	2020/8/1	104.13	F	55	51.5	112	73	121	7.6	28.1	51.2	8.18	2.41	5.73	5.4	55.7	101.30	11	6PR
91	90	NS	MN	TAC	5.8	2020/8/1	＞1500	F	73	58	128	77	145	8.7	27.9	60.2	4.68	2.7	2.65	4.8	64.1	82.63	11	0
92	91	NS	MN	TAC+glucocorticoid	6.5	2020/8/1	111.75	M	64	56.5	108	64	137	3.34	24.5	49.9	10.19	7.79	2.55	5.63	68.6	95.59	12	0
93	92	NS	MN	TAC+glucocorticoid	4.9	2020/9/1	＞1500	M	68	70	155	89	130	3.86	14.9	47.9	10.39	1.93	7.56	10.6	104.7	62.75	6	0	soft tissue infection、chronic renal insufficiency
94	93	NS	MN	TAC+glucocorticoid	6.9	2020/9/1	84.53	M	64	71.6	142	93	153	4.71	30	55.1	6.98	1.96	4.63	2.8	70.3	94.64	13	3PR
95	94	NS	MN	TAC	5.2	2020/9/1	＞1500	M	70	79	135	85	137	3.68	16	50.5	9.23	1.31	7.44	3.7	67.3	92.37	9	9PR	Pulmonary infection、septic shock、interstitial pneumonia、AKI、Diabetes
96
97
98
99
100